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Vaping devices first entered the US market in 2006 and 
have been aggressively marketed. Most of these devices 
do not resemble tobacco products but rather have the 
appearance of everyday use materials such as pens and 
USB flash drives which are both easy to carry and hide. 
Here we review what is known about VAPI. The ATS 
Patient Education series previously published a review 
document highlighting the risks of electronic nicotine 
delivery systems2. Some believe that vaping is safer than 
traditional cigarettes, but the short- and long-term health 
effects of vaping are increasingly worrisome.  
Clinical Presentation
To date, the CDC has reported an epidemic of 
“severe lung disease” caused by vaping. Patients 
have presented with a range of symptoms, including 
shortness of breath, fever, cough, vomiting, diarrhea, 
headache, dizziness and chest pain following the use 
of vaping devices. Symptoms typically worsened over 
a period of days to weeks before patients were seen 
by a healthcare provider, and were consistent with 
chemical pneumonitis. Many patients have required 
hospitalization, and several have required ICU-
level care with mechanical ventilation due to severe 
respiratory failure. As of September 16th 2019, the CDC 
has confirmed six deaths attributed to VAPI, and is 
evaluating over 350 cases.
Pathophysiology
The etiology of VAPI is as yet unknown, but it does not 
appear to be infection-mediated. There are multiple 
compounds present in vaporized material that could 
potentially cause injury such as flavorants (e.g. diacetyl, a 
chemical linked to serious lung disease); volatile organic 
compounds; and heavy metals (e.g. nickel, tin, and lead). 
The U.S. Food and Drug Administration’s Center for 
Tobacco Products is analyzing product samples from 
vaping devices across multiple states to identify any 
potentially harmful constituents that may be triggering 
the illnesses. VAPI has been reported with a range of 
vaping devices and liquids; no one specific liquid or device 
has been identified as the causative agent. VAPI has been 
reported with nicotine, tetrahydrocannabinol (THC) and 
cannabidiol (CBD) products.
Laboratory findings and Imaging
Associated lab findings in patients with VAPI are variable 
and non-specific. They include elevated white blood cell 
count and erythrocyte sedimentation rate. CT imaging 
demonstrates infiltrates in both lungs (Layden J. E. et al 
NEJM 2019)3. Bronchoscopy with BAL most commonly 
demonstrates neutrophilia and sparse to moderate 
lipid laden macrophages by Oil Red O staining or Sudan 
staining.
Figure 2: CT findings of a patient with acute VAPI
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As of September 2019, the Centers for Disease 
Control (CDC) has reported over 350 cases of vaping-
associated pulmonary illness (VAPI) across 36 states. 
The observed patterns of disease are variable but all 
have been associated with recent electronic cigarette 
use or “vaping.” Vaping is a word used to describe the 
use of an electronic system to deliver inhaled drugs, 
most commonly nicotine and cannabinoids (natural or 
synthetic forms of marijuana)1. Juuling is another term 
that is used to describe the use of a specific vape device. 
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Diseases Associated with VAPI
The following patterns of lung injury have been reported 
with VAPI:
■■ Acute eosinophilic pneumonia
■■ Lipoid pneumonia
■■ Acute lung injury and acute respiratory distress 
syndrome
■■ Acute and subacute hypersensitivity pneumonitis
■■ Organizing pneumonia
■■ Acute eosinophilic pneumonia
■■ Diffuse alveolar hemorrhage
■■ Respiratory bronchiolitis-associated pneumonitis
Treatment
Based on limited experience to date, treatment with 
corticosteroids may improve symptoms in some cases. In 
addition, clinicians should seek to identify other causes 
of illness (e.g. infections) that may be contributing to the 
clinical presentation. Clinicians should inquire specifically 
about e-cigarette use in any patient presenting with 
acute lung disease. In patients suspected of VAPI, whom 
are candidates for bronchoscopy, it may be helpful 
to perform bronchoscopy with BAL for submission of 
samples for Oil Red O or Sudan staining and further 
infectious work-up to rule out other etiologies. The CDC 
also recommends that clinicians report cases of VAPI to 
their state or local health department, as well as the FDA 
at https://www.safetyreporting.hhs.gov/SRP2/en/Home.
aspx?sid=cc7873df-0590-49ec-9d71-ecbf742d34e3 and 
collect the following information4:
■■ Type of device(s) used (e.g. bottles, cartridges or pods)
■■ Specific type(s) of liquid used (e.g. nicotine, THC 
products, flavored fluids)
■■ Were devices, liquids, refill pods and/or cartridges 
shared with other people?
■■ Were old cartridges or pods reused with other 
homemade or commercial products?
■■ Were devices used to inhale drugs that were 
concentrated by heating prior to vaping (i.e., 
“dabbing”)
■■ Details of vaping behavior (e.g. cloud volume, 
frequency of puffs, ‘zero’ or ‘stealth’ vaping, valsalva at 
end inhalation).
Contacting the CDC
The CDC is actively assisting state health departments 
with their epidemiological and laboratory investigations 
by facilitating information sharing between state health 
departments, providing assistance in the development of 
data collection tools and health communication materials, 
and identifying options to facilitate laboratory testing of 
vaping products and solutions. Public health officials can 
discuss possible cases, receive guidance on laboratory 
testing, and obtain assistance with epidemiological 
investigations by emailing: VapingAssocIllness@cdc.gov.
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R Action Steps
 ✔ Report all suspected cases to CDC.
 ✔ Screen all patients for the use of tobacco and 
vaping devices.
 ✔ Offer smoking and vaping cessation counseling to 
all patients who report use.
 ✔ Support legislation to prevent the sale of vaping and 
tobacco products to anyone under the age of 21.
 ✔ Support stronger penalties for retailers who illegally 
sell tobacco, nicotine, and vaping devices to minors.
 ✔ Encourage the FDA and Congress to ban flavors in 
tobacco products.
 ✔ Support research on prevention and cessation 
strategies for smoking and vaping.
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